Literature DB >> 30110632

RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair.

Lavina Sierra Tay1, Vaidehi Krishnan2, Haresh Sankar1, Yu Lin Chong1, Linda Shyue Huey Chuang1, Tuan Zea Tan1, Arun Mouli Kolinjivadi1, Dennis Kappei1, Yoshiaki Ito3.   

Abstract

The Fanconi anemia (FA) pathway is a pivotal genome maintenance network that orchestrates the repair of DNA interstrand crosslinks (ICLs). The tumor suppressors RUNX1 and RUNX3 were shown to regulate the FA pathway independent of their canonical transcription activities, by controlling the DNA damage-dependent chromatin association of FANCD2. Here, in further biochemical characterization, we demonstrate that RUNX3 is modified by PARP-dependent poly(ADP-ribosyl)ation (PARylation), which in turn allows RUNX binding to DNA repair structures lacking transcription-related RUNX consensus motifs. SILAC-based mass spectrometric analysis revealed significant association of RUNX3 with core DNA repair complexes, including PARP1, even in unstressed cells. After DNA damage, the increased interaction between RUNX3 and BLM facilitates efficient FANCD2 chromatin localization. RUNX-Walker motif mutations from breast cancers are impaired for DNA damage-inducible PARylation, unveiling a potential mechanism for FA pathway inactivation in cancers. Our results reinforce the emerging paradigm that RUNX proteins are tumor suppressors with genome gatekeeper function.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BLM; DNA repair; FANCD2; Fanconi anemia; PARP1; RUNX1; RUNX3; SILAC; interstrand crosslink repair; poly(ADP-ribosyl)ation

Mesh:

Substances:

Year:  2018        PMID: 30110632     DOI: 10.1016/j.celrep.2018.07.038

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  10 in total

1.  Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat.

Authors:  Manabu Taura; Eric Song; Ya-Chi Ho; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-22       Impact factor: 11.205

2.  Functional relationship between p53 and RUNX proteins.

Authors:  Suk-Chul Bae; Arun Mouli Kolinjivadi; Yoshiaki Ito
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

Review 3.  Role of RUNX Family Transcription Factors in DNA Damage Response.

Authors:  Ann Sanoji Samarakkody; Nah-Young Shin; Alan B Cantor
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

Review 4.  RUNX1 Dosage in Development and Cancer.

Authors:  Michael Lie-A-Ling; Renaud Mevel; Rahima Patel; Karen Blyth; Esther Baena; Valerie Kouskoff; Georges Lacaud
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 4.250

5.  MORC2 regulates DNA damage response through a PARP1-dependent pathway.

Authors:  Lin Zhang; Da-Qiang Li
Journal:  Nucleic Acids Res       Date:  2019-09-19       Impact factor: 16.971

6.  DGCR8/miR-106 Axis Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinomas by Downregulating RUNX3.

Authors:  Chunlin Zhang; Hangqi Chen; Zeyi Deng; Dan Long; Li Xu; Zhaohui Liu
Journal:  Front Med (Lausanne)       Date:  2020-12-15

Review 7.  The Multiple Interactions of RUNX with the Hippo-YAP Pathway.

Authors:  Linda Shyue Huey Chuang; Yoshiaki Ito
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

Review 8.  Runx Transcription Factors in T Cells-What Is Beyond Thymic Development?

Authors:  Svetlana Korinfskaya; Sreeja Parameswaran; Matthew T Weirauch; Artem Barski
Journal:  Front Immunol       Date:  2021-08-06       Impact factor: 7.561

9.  The H. pylori CagA Oncoprotein Induces DNA Double Strand Breaks through Fanconi Anemia Pathway Downregulation and Replication Fork Collapse.

Authors:  Arun Mouli Kolinjivadi; Haresh Sankar; Ramveer Choudhary; Lavina Sierra Tay; Tuan Zea Tan; Naoko Murata-Kamiya; Dominic Chih-Cheng Voon; Dennis Kappei; Masanori Hatakeyama; Vaidehi Krishnan; Yoshiaki Ito
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

Review 10.  Targeting dePARylation for cancer therapy.

Authors:  Muzaffer Ahmad Kassab; Lily L Yu; Xiaochun Yu
Journal:  Cell Biosci       Date:  2020-01-29       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.